Related Experiment Video
Updated: Aug 3, 2026
07:14
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
Monoclonal antibody JC1: new reagent for studying cell proliferation
M C Garrido1, J L Cordell, M H Becker
1Nuffield Department of Pathology, John Radcliffe Hospital, Oxford.
Journal of Clinical Pathology
|October 1, 1992
Summary
A new antibody, JC1, identifies a nuclear antigen in proliferating cells, distinct from Ki67. JC1 shows promise as a proliferation marker, especially in squamous cell carcinomas where Ki67 is less effective.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Proliferating cells express specific nuclear antigens.
- Accurate identification of proliferating cells is crucial for cancer diagnosis and research.
- Existing markers like Ki67 have limitations in certain contexts.
Purpose of the Study:
- To characterize a novel mouse monoclonal antibody, JC1.
- To evaluate JC1's ability to recognize a nuclear antigen in proliferating cells.
- To compare JC1's performance with the established proliferation marker, Ki67.
Main Methods:
- Immunohistochemical staining of normal tissues and tumors using JC1 and Ki67 antibodies.
- Western blot analysis to determine the molecular weight of the antigen recognized by JC1.
- Testing of JC1 against recombinant Ki67 protein.
Main Results:
- JC1 recognizes a nuclear antigen with molecular weights of 212 and 123 kDa, distinct from Ki67 (395-345 kDa).
- JC1 shows reactivity in proliferating cells in various normal tissues and tumors, similar to Ki67.
- JC1 exhibits nuclear reactivity only and lacks cytoplasmic cross-reactivity seen with Ki67 in squamous cells. JC1 identified more cells in testis than Ki67.
Conclusions:
- JC1 is a novel antibody recognizing a nuclear antigen in proliferating cells.
- JC1 serves as a valuable adjunct to Ki67 for assessing cell proliferation.
- JC1 is particularly useful for proliferation assessment in squamous cell carcinomas where Ki67 determination is challenging.
